• Backgrounder: May2008 Kinase Meeting (PDF)

• Poster: Co-Crystal Structures of 7-Azaindole Inhibitors Bound to Wild-Type and Mutant Abl Kinase. The American Society of Hematology 49th Annual Meeting and Exposition, December 2007 (PDF)

• Presentation: Fragment-Based Discovery of Selective, Orally Bioavailable Tyrosine Kinase Inhibitors for Targeted Treatment of Human Cancers. eCheminfo Latest Advances in Drug Discovery & Development InterAction Meeting, October 2007 (PDF)

• Poster: In Vitro and In Vivo Anti-Tumor Activities of SGX523, a Novel MET Inhibitor. AACR-NCI-EORTC International Conference, October 2007 (PDF)

• Poster: Selective Inhibition of MET Protein Receptor Tyrosine Kinase by SGX523. AACR-NCI-EORTC International Conference, October 2007 (PDF)

• Presentation: From Fragments to Drug Candidates: Application of Structure-Based Drug Design. Gordon Research Conference on Medicinal Chemistry, August 2007 (PDF)

• Poster: (SGX523) A Potent and Highly Selective Small Molecule Inhibitor of the MET Receptor Tyrosine Kinase. AACR Annual Meeting, April 2007 (PDF)

• Poster: (SGX393) Inhibition of BCR-ABL and Other Imatinib-Resistant BCR-ABL Mutants by the Selective ABL Kinase Inhibitor. ASH Annual Meeting, October 2006 (PDF)

Publications:

• Ohare, Thomas, Eide, Christopher, Tyner, Jeffrey, et al.(2008).  SGX393 inhibits the CML mutant BCR-ABL(T315I) and preempts in vitro resistance when combined with nilotinib or dasatinib. PNAS, Vol. 105, no.14, 5507-5512.